Increasing market share in Japan’s generic pharmaceuticals market
First written in FY2022-Q1. 4 of 14 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Update of latest results and regulatory changesAnnual report
「Under the fiscal 2026 drug-price revision, a system was introduced under which the listed price at launch of authorized generic drugs is set at the same level as that of the corresponding originator drug. This is expected to contribute to stable supply by improving the accuracy of supply planning at the time of new market entry.」
The generic-drug volume share was updated to 88.8% based on the government’s September 2025 preliminary survey, and the new pricing system for authorized generic drugs under the fiscal 2026 drug-price revision was also disclosed. - 2026-05-15OtherEarnings
「The latest preliminary government survey of drug prices, conducted in September 2025, shows that generic drugs accounted for 88.8% of volume.」
The latest preliminary figure for the government's generic-drug volume share was updated. The disclosure also states the targets of a volume share of at least 80% and a value share of at least 65% by the end of fiscal 2029, among others. - FY2026-H1Addition of value-share resultsAnnual report
「The value share of generic drugs in the government’s September 2024 drug-price survey was 62.1%.」
In addition to the previously reported volume share of 85.0%, the value share of generic drugs based on the September 2024 survey, at 62.1%, was newly disclosed. The targets for the end of fiscal 2029, including a volume share of at least 80% and a value share of at least 65%, remain in place. - FY2025Update to latest resultsAnnual report
「As a result, the latest generic drug volume share, based on the government’s September 2024 drug price survey (preliminary figure), was 85.0%.」
The government’s generic drug volume share was updated from the previously reported 80.2% (preliminary figure) to 85.0% (preliminary figure based on the September 2024 survey). The roadmap’s targets of a volume share of at least 80% and a value share of at least 65% in every prefecture by the end of fiscal 2029, together with the biosimilar-related targets, remain in place. - FY2025-H1Reflection of revised government roadmapAnnual report
「In addition, at the Health Insurance Subcommittee of the Social Security Council in September 2024, the government revised its “Roadmap for Further Promoting the Use of Generic Drugs.” The numerical targets were: “Main target: a generic-drug volume share of at least 80% in every prefecture by the end of fiscal 2029, with stable pharmaceutical supply as the basic premise (carried over from the previous roadmap)”; “Secondary target 1: by the end of fiscal 2029, the number of active ingredients for which biosimilars account for at least 80% of use to represent at least 60% of all active ingredients”; and “Secondary target 2: a generic-drug value share of at least 65% by the end of fiscal 2029.”」
The September 2024 revision of the government roadmap was reflected, adding a biosimilar-related secondary target to the existing volume- and value-share targets. - FY2024Update to government targetsAnnual report
「At the Health Insurance Subcommittee of the Social Security Council in March 2024, the main target was set at achieving a generic-drug volume share of at least 80% in every prefecture by the end of fiscal 2029, while maintaining stable pharmaceutical supply as the basic premise. A secondary target of achieving a generic-drug value share of at least 65% by the end of fiscal 2029 was also established.」
The deadline for the government’s 80% volume-share target was extended to the end of fiscal 2029, and a new secondary target of at least 65% by value was added. - FY2024-Q3Update to latest resultsAnnual report
「As a result, the latest generic-drug volume share in the government’s September 2023 drug-price survey was 80.2% (preliminary figure). From October 2024, additional patient charges are scheduled to apply to certain long-listed products for which generic drugs are available, which is expected to further increase the use of generic drugs.」
The government’s generic-drug volume share was updated from the previously reported 79.0% (preliminary) to 80.2% (preliminary). The government’s target of at least 80% in every prefecture by the end of fiscal 2023 and the scheduled additional patient charges from October 2024 were also stated. - FY2024-Q1Update from preliminary to final figureAnnual report
「As a result, the latest generic-drug volume share in the government’s September 2022 drug-price survey was 79.0% (final figure).」
The previously reported figure of 79.0% (preliminary) was updated to the final figure. The government’s target of at least 80% in every prefecture by the end of fiscal 2023 remained unchanged. - FY2023-Q3Update to latest resultsAnnual report
「The “Basic Policy on Economic and Fiscal Management and Reform 2021,” approved by the Cabinet in June 2021, states that the government will ensure the quality and reliability of generic-drug production and stable supply, strengthen manufacturing management systems, tighten oversight of manufacturing sites, conduct quality inspections of products in distribution, and raise the volume share of generic drugs to at least 80% in every prefecture by the end of fiscal 2023. The latest generic-drug volume share in the government’s September 2022 drug-price survey was 79.0% (preliminary figure).」
The government’s target of a volume share of at least 80% by the end of fiscal 2023 was maintained, while the latest government survey figure was updated to 79.0% (preliminary figure). - FY2023-Q2RestatedAnnual report
「The policy is to achieve a generic drug volume share of at least 80% in every prefecture by the end of fiscal 2023. The latest generic drug utilization rate, based on the government’s September 2021 drug price survey, was 79.2%.」
The policy of increasing the domestic generic pharmaceuticals market share continues, with the latest utilization rate of 79.2% reported against the government’s 80% target. - FY2023-Q1RestatedAnnual report
「The three pillars are “expanding market share in Japan’s generic pharmaceuticals market,” “business investment to support future growth in the U.S. business,” and “developing new growth areas.”」
Expanding market share in Japan’s generic pharmaceuticals market is reiterated as one of the three pillars of the long-term vision. - FY2022RestatedAnnual report
「In this environment, under the medium-term management plan, as a leading company in the generic pharmaceuticals industry, we are working to restore confidence in the industry as a whole and expand our share of Japan’s generic pharmaceuticals market by further strengthening quality control, increasing sales of new products, and reinforcing our ability to ensure stable supply.」
Expanding market share in Japan’s generic pharmaceuticals market remains a primary objective, with quality, new products and stable supply identified as the means of achieving it. - FY2022-Q2RestatedAnnual report
「The three pillars are “expanding market share in Japan’s generic pharmaceuticals market,” “business investment to support future growth in the U.S. business,” and “developing new growth areas.”」
The expansion of market share in Japan’s generic pharmaceuticals market is reiterated as a pillar of the long-term vision. The government’s policy of achieving a volume share of 80% or more for generics in every prefecture by the end of fiscal 2023 is also described. - FY2022-Q1First statedAnnual report
「The three pillars are “increasing our share of the domestic generic pharmaceuticals market,” “business investment to support future growth in the U.S. business,” and “developing new growth areas.”」
Increasing market share in Japan’s generic pharmaceuticals market is explicitly identified as one of the three pillars of the long-term vision.